S&P 500   3,967.70 (+0.86%)
DOW   33,858.09 (+0.77%)
QQQ   284.09 (+1.27%)
AAPL   143.14 (+1.56%)
MSFT   246.12 (+0.72%)
META   115.33 (+1.23%)
GOOGL   94.11 (-0.87%)
AMZN   90.60 (+2.42%)
TSLA   174.95 (+0.52%)
NVDA   167.91 (+4.16%)
NIO   13.39 (+6.44%)
BABA   93.08 (+5.38%)
AMD   70.86 (+1.03%)
T   19.26 (-0.21%)
MU   55.41 (+2.95%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   84.81 (-0.22%)
DIS   92.82 (+0.73%)
AMC   6.39 (+5.62%)
PYPL   75.58 (+1.56%)
PFE   50.59 (+0.70%)
NFLX   311.36 (+0.95%)
S&P 500   3,967.70 (+0.86%)
DOW   33,858.09 (+0.77%)
QQQ   284.09 (+1.27%)
AAPL   143.14 (+1.56%)
MSFT   246.12 (+0.72%)
META   115.33 (+1.23%)
GOOGL   94.11 (-0.87%)
AMZN   90.60 (+2.42%)
TSLA   174.95 (+0.52%)
NVDA   167.91 (+4.16%)
NIO   13.39 (+6.44%)
BABA   93.08 (+5.38%)
AMD   70.86 (+1.03%)
T   19.26 (-0.21%)
MU   55.41 (+2.95%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   84.81 (-0.22%)
DIS   92.82 (+0.73%)
AMC   6.39 (+5.62%)
PYPL   75.58 (+1.56%)
PFE   50.59 (+0.70%)
NFLX   311.36 (+0.95%)
S&P 500   3,967.70 (+0.86%)
DOW   33,858.09 (+0.77%)
QQQ   284.09 (+1.27%)
AAPL   143.14 (+1.56%)
MSFT   246.12 (+0.72%)
META   115.33 (+1.23%)
GOOGL   94.11 (-0.87%)
AMZN   90.60 (+2.42%)
TSLA   174.95 (+0.52%)
NVDA   167.91 (+4.16%)
NIO   13.39 (+6.44%)
BABA   93.08 (+5.38%)
AMD   70.86 (+1.03%)
T   19.26 (-0.21%)
MU   55.41 (+2.95%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   84.81 (-0.22%)
DIS   92.82 (+0.73%)
AMC   6.39 (+5.62%)
PYPL   75.58 (+1.56%)
PFE   50.59 (+0.70%)
NFLX   311.36 (+0.95%)
S&P 500   3,967.70 (+0.86%)
DOW   33,858.09 (+0.77%)
QQQ   284.09 (+1.27%)
AAPL   143.14 (+1.56%)
MSFT   246.12 (+0.72%)
META   115.33 (+1.23%)
GOOGL   94.11 (-0.87%)
AMZN   90.60 (+2.42%)
TSLA   174.95 (+0.52%)
NVDA   167.91 (+4.16%)
NIO   13.39 (+6.44%)
BABA   93.08 (+5.38%)
AMD   70.86 (+1.03%)
T   19.26 (-0.21%)
MU   55.41 (+2.95%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   84.81 (-0.22%)
DIS   92.82 (+0.73%)
AMC   6.39 (+5.62%)
PYPL   75.58 (+1.56%)
PFE   50.59 (+0.70%)
NFLX   311.36 (+0.95%)
NASDAQ:SRPT

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$120.91
+1.15 (+0.96%)
(As of 12/8/2022 10:40 AM ET)
Add
Compare
Today's Range
$118.95
$121.46
50-Day Range
$100.39
$126.25
52-Week Range
$61.28
$127.32
Volume
3,158 shs
Average Volume
844,859 shs
Market Capitalization
$10.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$143.91

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
20.2% Upside
$143.91 Price Target
Short Interest
Healthy
8.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$5.96 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($8.21) to ($3.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

271st out of 1,027 stocks

Pharmaceutical Preparations Industry

115th out of 503 stocks

SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Robert W. Baird Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sarepta’s Gene Therapy Set for Quick FDA Review
Sarepta Therapeutics (NASDAQ:SRPT) Sets New 52-Week High at $124.00
Sarepta Therapeutics Unusual Options Activity
Sarepta Therapeutics Up For Earnings Revenue Surprise
10 Best Pharma Stocks To Buy Now
7 Analysts Have This to Say About Sarepta Therapeutics
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/02/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$143.91
High Stock Price Forecast
$190.00
Low Stock Price Forecast
$101.00
Forecasted Upside/Downside
+19.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-81.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share

Miscellaneous

Free Float
82,165,000
Market Cap
$10.61 billion
Optionable
Optionable
Beta
1.08

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 59)
    Pres, CEO & Director
    Comp: $1.55M
  • Mr. Ian Michael Estepan (Age 46)
    Exec. VP & CFO
    Comp: $861.75k
  • Mr. William F. Ciambrone (Age 58)
    Exec. VP of Technical Operations
    Comp: $780.28k
  • Dr. Louise R. Rodino-Klapac Ph.D.Dr. Louise R. Rodino-Klapac Ph.D. (Age 44)
    Exec. VP, Chief Scientific Officer and Head of R&D
    Comp: $929.68k
  • Mr. Ryan E. Brown (Age 44)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $913.64k
  • Bilal Arif
    Sr. VP of Strategy and Operations
  • Mary Jenkins
    Sr. Mang. of Investor Relations
  • Ms. Alison Nasisi
    Chief People Officer & VP
  • Dr. Diane L. Berry
    Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Mr. Dallan Murray
    Sr. VP & Chief Customer Officer













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

8 brokers have issued twelve-month price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $101.00 to $190.00. On average, they predict the company's share price to reach $143.91 in the next year. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2022?

Sarepta Therapeutics' stock was trading at $90.05 at the start of the year. Since then, SRPT stock has increased by 33.0% and is now trading at $119.76.
View the best growth stocks for 2022 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, November, 2nd. The biotechnology company reported ($2.94) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by $1.73. The biotechnology company had revenue of $230.30 million for the quarter, compared to analyst estimates of $234.55 million. Sarepta Therapeutics had a negative net margin of 81.76% and a negative trailing twelve-month return on equity of 97.37%. Sarepta Therapeutics's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.60) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.21%), EcoR1 Capital LLC (3.42%), Sands Capital Management LLC (2.83%), Price T Rowe Associates Inc. MD (1.39%), Assenagon Asset Management S.A. (1.29%) and First Trust Advisors LP (1.04%). Insiders that own company stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry, Sandesh Mahatme and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $119.76.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.51 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($8.21) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 12/8/2022 by MarketBeat.com Staff